Bryhali News a Positive for Bausch Health (BHC) - Mizuho

Mizuho Securities analyst Irina Koffler reiterated a Buy rating and $35 price target on Bausch Health Companies (NYSE: BHC) after Bryhali received tentative FDA approval. Koffler called this a "positive catalyst" for the company.

"While we don't yet have an approved label, we can glean from the press release that Bryhali may be a slightly milder and more tolerable form of Ultravate," Koffler commented. "For example, Bryhali did not show skin atrophy after 8 weeks of dosing (and this adverse event was detected in Ultravate after 2 weeks of treatment). Also, 1% of patients in the Ultravate trials developed spider veins after 2 weeks of treatment. It is still unclear if Bryhali will be labeled for longer-term use but we are encouraged by the press release which hints at tolerability benefits over Ultravate and a longer dosing regimen."

For an analyst ratings summary and ratings history on Bausch Health Companies click here. For more ratings news on Bausch Health Companies click here.

Shares of Bausch Health Companies closed at $26.70 yesterday.

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
• Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)